SCHEMBL607175

SCHEMBL607175

Cc1ccccc1CNCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.67
CHRM2 P08172 2/20 0.58
PKM P14618 1/20 0.58
DRD4 P21917 1/20 0.53
DRD3 P35462 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALDH1A1 P00352 3/20 0.51
TP53 P04637 1/20 0.50
THRB P10828 1/20 0.50
SCN8A Q9UQD0 1/20 0.49
HPGD P15428 1/20 0.49
BCHE P06276 1/20 0.47
MAOA P21397 1/20 0.47
MPO P05164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10781346 0.90 HTT (0.56) HTTCHRM2PKMDRD4DRD3
SCHEMBL40401 0.89 CHRM2 (0.69) HTTCHRM2MEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL6065696 0.87 CHRM2 (0.67) HTTCHRM2PKMMEN1KMT2A
SCHEMBL25377223 0.86 PKM (0.53) HTTCHRM2PKMDRD4DRD3
SCHEMBL6613481 0.85 HTT (0.55) HTTCHRM2PKMDRD4DRD3
SCHEMBL25375887 0.85 HTT (0.55) HTTCHRM2DRD4DRD3L3MBTL1
SCHEMBL14492294 0.85 MAPK1 (0.60) HTTCHRM2MEN1KMT2AALDH1A1
SCHEMBL9080908 0.84 KDM4E (0.56) HTTCHRM2PKMMEN1KMT2A
SCHEMBL11881191 0.84 PKM (0.69) CHRM2PKMMEN1KMT2ATDP1
SCHEMBL11876690 0.83 PKM (0.53) HTTCHRM2PKMDRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US claimed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 EP claimed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 WO claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US claimed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US disclosed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 EP disclosed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 WO disclosed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
EP-1230240-B1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOLIDINONE ALPHA V INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2003-07-23 EP disclosed
CN-1414966-A Process and intermediates for preparation of imidazolidinone alpha U protein antagonists MERCK & CO INC (US) 2003-04-30 CN disclosed
EP-1230240-A2 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOLIDINONE ALPHA V INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 2002-08-14 EP disclosed
US-6407241-B1 REACTING THE CORRESPONDING WITH AMINE AND PHOSGENE; CYCLIZATION; THERAPY FOR BONE DISORDERS; ANTIINFLAMMATORY AGENTS MERCK & CO., INC. 2002-06-18 US disclosed
WO-2001034602-A2 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOLIDINONE ALPHA V INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 2001-05-17 WO disclosed
EP-0659178-A4 CHIRAL QUINOLONE INTERMEDIATES. ABBOTT LAB (US) 1996-03-27 EP disclosed
EP-0659178-A1 CHIRAL QUINOLONE INTERMEDIATES ABBOTT LABORATORIES (US) 1995-06-28 EP disclosed
WO-1994006766-A1 CHIRAL QUINOLONE INTERMEDIATES ABBOTT LABORATORIES (US) 1994-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 HTT 3855/4885CHRM2 461/4885PKM 3429/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 HTT 3800/4885CHRM2 2271/4885PKM 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.